How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
30
CASI Quote, Financials, Valuation and Earnings
Last price:
$1.01
Seasonality move
:
8.65%
Day range:
$0.99 - $1.03
52-week range:
$0.75 - $3.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.59x
P/B ratio:
15.65x
Volume:
52K
Avg. volume:
43.4K
1-year change:
-59.12%
Market cap:
$21M
Revenue:
$28.5M
EPS (TTM):
-$3.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
ANL
Adlai Nortye Ltd.
|
-- | -$1.31 | -- | -33.06% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$126.7M | -$0.42 | 20.26% | -35.1% | $44.92 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CASI
CASI Pharmaceuticals, Inc.
|
$1.02 | $4.00 | $21M | -- | $0.00 | 0% | 0.59x |
|
ADAG
Adagene, Inc.
|
$2.75 | $9.22 | $129.6M | -- | $0.00 | 0% | 1,237.65x |
|
ANL
Adlai Nortye Ltd.
|
$10.63 | -- | $392.3M | -- | $0.00 | 0% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
$1.13 | -- | $3.7M | -- | $0.00 | 0% | 0.91x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$16.60 | $44.92 | $1.8B | -- | $0.00 | 0% | 4.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.497 | 55.28% | 0.19x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.358 | -- | 2.23x |
|
ANL
Adlai Nortye Ltd.
|
-- | -0.187 | -- | -- |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.111 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 6.279 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.105 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
ANL
Adlai Nortye Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
CASI Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns CASI or ADAG?
Adagene, Inc. has a net margin of -353.92% compared to CASI Pharmaceuticals, Inc.'s net margin of --. CASI Pharmaceuticals, Inc.'s return on equity of -70405.41% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About CASI or ADAG?
CASI Pharmaceuticals, Inc. has a consensus price target of $4.00, signalling upside risk potential of 292.16%. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 235.43%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Adagene, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Adagene, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASICASI Pharmaceuticals, Inc.1 0 0 ADAGAdagene, Inc.6 2 0 -
Is CASI or ADAG More Risky?
CASI Pharmaceuticals, Inc. has a beta of 0.825, which suggesting that the stock is 17.505% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CASI or ADAG?
CASI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASI or ADAG?
CASI Pharmaceuticals, Inc. quarterly revenues are $3.1M, which are larger than Adagene, Inc. quarterly revenues of --. CASI Pharmaceuticals, Inc.'s net income of -$10.9M is higher than Adagene, Inc.'s net income of --. Notably, CASI Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals, Inc. is 0.59x versus 1,237.65x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASICASI Pharmaceuticals, Inc.0.59x -- $3.1M -$10.9M ADAGAdagene, Inc.1,237.65x -- -- --
-
Which has Higher Returns CASI or ANL?
Adlai Nortye Ltd. has a net margin of -353.92% compared to CASI Pharmaceuticals, Inc.'s net margin of --. CASI Pharmaceuticals, Inc.'s return on equity of -70405.41% beat Adlai Nortye Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M ANLAdlai Nortye Ltd.-- -- -- -
What do Analysts Say About CASI or ANL?
CASI Pharmaceuticals, Inc. has a consensus price target of $4.00, signalling upside risk potential of 292.16%. On the other hand Adlai Nortye Ltd. has an analysts' consensus of -- which suggests that it could fall by -15.33%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Adlai Nortye Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Adlai Nortye Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CASICASI Pharmaceuticals, Inc.1 0 0 ANLAdlai Nortye Ltd.0 1 0 -
Is CASI or ANL More Risky?
CASI Pharmaceuticals, Inc. has a beta of 0.825, which suggesting that the stock is 17.505% less volatile than S&P 500. In comparison Adlai Nortye Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CASI or ANL?
CASI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adlai Nortye Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Adlai Nortye Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASI or ANL?
CASI Pharmaceuticals, Inc. quarterly revenues are $3.1M, which are larger than Adlai Nortye Ltd. quarterly revenues of --. CASI Pharmaceuticals, Inc.'s net income of -$10.9M is higher than Adlai Nortye Ltd.'s net income of --. Notably, CASI Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Adlai Nortye Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals, Inc. is 0.59x versus -- for Adlai Nortye Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASICASI Pharmaceuticals, Inc.0.59x -- $3.1M -$10.9M ANLAdlai Nortye Ltd.-- -- -- --
-
Which has Higher Returns CASI or CPHI?
China Pharma Holdings, Inc. has a net margin of -353.92% compared to CASI Pharmaceuticals, Inc.'s net margin of -86.16%. CASI Pharmaceuticals, Inc.'s return on equity of -70405.41% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About CASI or CPHI?
CASI Pharmaceuticals, Inc. has a consensus price target of $4.00, signalling upside risk potential of 292.16%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CASI Pharmaceuticals, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASICASI Pharmaceuticals, Inc.1 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is CASI or CPHI More Risky?
CASI Pharmaceuticals, Inc. has a beta of 0.825, which suggesting that the stock is 17.505% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.033, suggesting its more volatile than the S&P 500 by 3.259%.
-
Which is a Better Dividend Stock CASI or CPHI?
CASI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASI or CPHI?
CASI Pharmaceuticals, Inc. quarterly revenues are $3.1M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. CASI Pharmaceuticals, Inc.'s net income of -$10.9M is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, CASI Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals, Inc. is 0.59x versus 0.91x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASICASI Pharmaceuticals, Inc.0.59x -- $3.1M -$10.9M CPHIChina Pharma Holdings, Inc.0.91x -- $756.2K -$651.5K
-
Which has Higher Returns CASI or SVA?
Sinovac Biotech Ltd. has a net margin of -353.92% compared to CASI Pharmaceuticals, Inc.'s net margin of --. CASI Pharmaceuticals, Inc.'s return on equity of -70405.41% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CASI or SVA?
CASI Pharmaceuticals, Inc. has a consensus price target of $4.00, signalling upside risk potential of 292.16%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CASICASI Pharmaceuticals, Inc.1 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CASI or SVA More Risky?
CASI Pharmaceuticals, Inc. has a beta of 0.825, which suggesting that the stock is 17.505% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.623%.
-
Which is a Better Dividend Stock CASI or SVA?
CASI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. CASI Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios CASI or SVA?
CASI Pharmaceuticals, Inc. quarterly revenues are $3.1M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. CASI Pharmaceuticals, Inc.'s net income of -$10.9M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, CASI Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals, Inc. is 0.59x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASICASI Pharmaceuticals, Inc.0.59x -- $3.1M -$10.9M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CASI or ZLAB?
Zai Lab Ltd. has a net margin of -353.92% compared to CASI Pharmaceuticals, Inc.'s net margin of -30.98%. CASI Pharmaceuticals, Inc.'s return on equity of -70405.41% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About CASI or ZLAB?
CASI Pharmaceuticals, Inc. has a consensus price target of $4.00, signalling upside risk potential of 292.16%. On the other hand Zai Lab Ltd. has an analysts' consensus of $44.92 which suggests that it could grow by 170.6%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Zai Lab Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CASICASI Pharmaceuticals, Inc.1 0 0 ZLABZai Lab Ltd.9 1 0 -
Is CASI or ZLAB More Risky?
CASI Pharmaceuticals, Inc. has a beta of 0.825, which suggesting that the stock is 17.505% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.508%.
-
Which is a Better Dividend Stock CASI or ZLAB?
CASI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASI or ZLAB?
CASI Pharmaceuticals, Inc. quarterly revenues are $3.1M, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. CASI Pharmaceuticals, Inc.'s net income of -$10.9M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, CASI Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals, Inc. is 0.59x versus 4.03x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASICASI Pharmaceuticals, Inc.0.59x -- $3.1M -$10.9M ZLABZai Lab Ltd.4.03x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
60
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
